Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness
- PMID: 29986372
- DOI: 10.1055/a-0643-4830
Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness
Abstract
In spite of multiple new treatment options, chronic and treatment refractory courses still are a major challenge in the treatment of depression. Providing algorithm-guided antidepressant treatments is considered an important strategy to optimize treatment delivery and avoid or overcome treatment-resistant courses of major depressive disorder (MDD). The clinical benefits of algorithms in the treatment of inpatients with MDD have been investigated in large-scale, randomized controlled trials. Results showed that a stepwise treatment regimen (algorithm) with critical decision points at the end of each treatment step based on standardized and systematic measurements of response and an algorithm-guided decision-making process increases the chances of achieving remission and optimizes prescription behaviors for antidepressants. In conclusion, research in MDD revealed that systematic and structured treatment procedures, the diligent assessment of response at critical decision points, and timely dose and treatment type adjustments make the substantial difference in treatment outcomes between algorithm-guided treatment and treatment as usual.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
Dr. Bauer has received consulting fees from Allergan, Janssen, Lundbeck, and Neuraxpharm and has received speaker honoraria from Lilly, Neuraxpharm, and Servier.Dr. Rush has received consulting fees from Akili Inc., the American Psychiatric Association, Brain Resource Ltd., Compass Inc., Curbstone Consultant LLC., Eli Lilly, Emmes Corp., Holmusk, Liva-Nova, Lundbeck A/S, National Institute of Drug Abuse, Santium Inc., Sunovion, Taj Medical, Takeda USA; speaking fees from Live Nova; and royalties from Guilford Publications and the University of Texas Southwestern Medical Center.Dr. Ricken has received a research grant, speaker honoraria, and congress fees from Aristo Pharma GmbH.Dr. Pilhatsch reports no biomedical financial interests or potential conflicts of interest.Dr. Adli has received grants/research support from the Alfred Herrhausen Society and Servier. He has received speaker honoraria from Deutsche Bank, the German Federal Agency for Civic Education, Schindler, ViiV, Gilead Sciences, MSD, Servier, Pfizer, Aristo, and Lundbeck and has been a consultant to Lundbeck, Merz, myTomorrows, Janssen-Cilag, Deutsche Bank, and MSD.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical